top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
27/08/2026 AbbVie submitted a regulatory application to the EMA for SC induction dosing of risankizumab in adults with moderately to severely active CD TEZSPIRE® demonstrated positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Argenx completed the acquisition of Forte Biosciences Priovant announced the US FDA approval of brepocitinib for adults with dermatomyositis AbbVie submitted a regulatory application to the EMA for
decodeMR Team
Aug 272 min read


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
17/08/2026 Argenx announced positive results from the phase 3 ALKIVIA study of efgartigimod in autoimmune myositis Argenx announced positive results from the phase 3 ALKIVIA study of efgartigimod in autoimmune myositis (Ref) Argenx announced positive topline results from the Phase 3, ALKIVIA/ NCT05523167 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. The study met its primary endpoint of mean Total Improvement
decodeMR Team
Aug 171 min read


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
03/03/2026 UCB and Antengene entered into a global license agreement for ATG-201 targeting B cell-related autoimmune diseases Johnson & Johnson received US FDA fast track designation for nipocalimab in SLE Priovant’s brepocitinib received US FDA acceptance and priority review for patients with dermatomyositis COUR Pharma announced Phase 2a results of CNP-104 in PBC Kyowa Kirin announced the discontinuation of rocatinlimab clinical trials UCB and Antengene entered into a globa
decodeMR Team
Mar 63 min read
bottom of page